|
|
|
|
| LEADER |
05542nma a2201441 u 4500 |
| 001 |
EB002048089 |
| 003 |
EBX01000000000000001191755 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a books978-3-0365-2538-9
|
| 020 |
|
|
|a 9783036525396
|
| 020 |
|
|
|a 9783036525389
|
| 100 |
1 |
|
|a Varanda, Carla
|
| 245 |
0 |
0 |
|a The Application of Viruses to Biotechnology
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2021
|
| 300 |
|
|
|a 1 electronic resource (296 p.)
|
| 653 |
|
|
|a codon optimization
|
| 653 |
|
|
|a LTR
|
| 653 |
|
|
|a gene therapy
|
| 653 |
|
|
|a CRISPR
|
| 653 |
|
|
|a macrophage
|
| 653 |
|
|
|a reduced generation time
|
| 653 |
|
|
|a infectious bursal disease virus
|
| 653 |
|
|
|a enhancer
|
| 653 |
|
|
|a pig
|
| 653 |
|
|
|a prophage
|
| 653 |
|
|
|a apple latent spherical virus vector
|
| 653 |
|
|
|a reverse genetics
|
| 653 |
|
|
|a Hypnocyclicus thermotrophus
|
| 653 |
|
|
|a AAV
|
| 653 |
|
|
|a RNA-based vaccines
|
| 653 |
|
|
|a Bacteriophage
|
| 653 |
|
|
|a carotenoid biosynthesis
|
| 653 |
|
|
|a bioreactor
|
| 653 |
|
|
|a Technology: general issues / bicssc
|
| 653 |
|
|
|a SARS-CoV-2
|
| 653 |
|
|
|a TMV
|
| 653 |
|
|
|a comparative genomics
|
| 653 |
|
|
|a expression vectors
|
| 653 |
|
|
|a theranostics
|
| 653 |
|
|
|a nanotechnology
|
| 653 |
|
|
|a recombinant Lactococcus lactis
|
| 653 |
|
|
|a VLP
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a infectious diseases
|
| 653 |
|
|
|a PVX
|
| 653 |
|
|
|a lytic cassette
|
| 653 |
|
|
|a circular RNA
|
| 653 |
|
|
|a variant strain
|
| 653 |
|
|
|a phages
|
| 653 |
|
|
|a viruses
|
| 653 |
|
|
|a prevention
|
| 653 |
|
|
|a grapevine
|
| 653 |
|
|
|a clodronate
|
| 653 |
|
|
|a genome editing
|
| 653 |
|
|
|a CRISPR/Cas systems
|
| 653 |
|
|
|a COVID-19 vaccines
|
| 653 |
|
|
|a vaccines
|
| 653 |
|
|
|a virus-induced gene silencing (VIGS)
|
| 653 |
|
|
|a plant genome engineering
|
| 653 |
|
|
|a immunization
|
| 653 |
|
|
|a chikungunya virus
|
| 653 |
|
|
|a plant virus
|
| 653 |
|
|
|a VNPs
|
| 653 |
|
|
|a Salmonella
|
| 653 |
|
|
|a biocontrol
|
| 653 |
|
|
|a diagnosis
|
| 653 |
|
|
|a codon harmonization
|
| 653 |
|
|
|a CRISPR/Cas9
|
| 653 |
|
|
|a adeno-associated virus
|
| 653 |
|
|
|a phage diversity
|
| 653 |
|
|
|a adeno-associated virus (AAV) vector
|
| 653 |
|
|
|a insect cells
|
| 653 |
|
|
|a Escherichia coli
|
| 653 |
|
|
|a cancer gene therapy
|
| 653 |
|
|
|a aspect ratio
|
| 653 |
|
|
|a Tn7
|
| 653 |
|
|
|a baculovirus
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a viral resistance
|
| 653 |
|
|
|a cancers
|
| 653 |
|
|
|a viral vectors
|
| 653 |
|
|
|a CPMV
|
| 653 |
|
|
|a genome stability
|
| 653 |
|
|
|a Newcastle disease virus
|
| 653 |
|
|
|a breeding of grapevine
|
| 653 |
|
|
|a viral vector
|
| 653 |
|
|
|a DNA-based vaccines
|
| 653 |
|
|
|a hydrothermal vent
|
| 653 |
|
|
|a heterologous expression
|
| 653 |
|
|
|a geminivirus
|
| 653 |
|
|
|a treatment
|
| 653 |
|
|
|a bacmid
|
| 653 |
|
|
|a vaccine
|
| 653 |
|
|
|a virus-induced flowering
|
| 653 |
|
|
|a transduction
|
| 653 |
|
|
|a VLPs
|
| 653 |
|
|
|a jaagsiekte sheep retrovirus (JSRV)
|
| 653 |
|
|
|a virus elimination
|
| 653 |
|
|
|a CRISPR-cas9
|
| 653 |
|
|
|a gene expression
|
| 653 |
|
|
|a protein expression
|
| 653 |
|
|
|a chemokines
|
| 653 |
|
|
|a porcine epidemic diarrhea virus
|
| 653 |
|
|
|a viroid
|
| 653 |
|
|
|a viral vaccines
|
| 653 |
|
|
|a gene editing
|
| 653 |
|
|
|a self-replicating RNA vectors
|
| 700 |
1 |
|
|a Materatski, Patrick
|
| 700 |
1 |
|
|a Varanda, Carla
|
| 700 |
1 |
|
|a Materatski, Patrick
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-2538-9
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/77123
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/4742
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 600
|
| 082 |
0 |
|
|a 620
|
| 520 |
|
|
|a Viruses are microscopic agents that exist worldwide and are present in humans, animals, plants, and other living organisms in which they can cause devastating diseases. However, the advances of biotechnology and next-generation sequencing technologies have accelerated novel virus discovery, identification, sequencing, and manipulation, showing that they present unique characteristics that place them as valuable tools for a wide variety of biotechnological applications. Many applications of viruses have been used for agricultural purposes, namely concerning plant breeding and plant protection. Nevertheless, it is interesting to mention that plants have also many advantages to be used in vaccine production, such as the low cost and low risks they entail, showing once more the versatility of the use of viruses in biotechnology. Although it will obviously never be ignored that viruses are responsible for devastating diseases, it is clear that the more they are studied, the more possibilities they offer to us. They are now on the front line of the most revolutionizing techniques in several fields, providing advances that would not be possible without their existence. In this book there are presented studies that demonstrate the work developed using viruses in biotechnology. These studies were brought by experts that focus on the development and applications of many viruses in several fields, such as agriculture, the pharmaceutical industry, and medicine.
|